FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy for Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) has granted approval for an allogeneic regulatory T cell-based immunotherapy that incorporates hematopoietic stem progenitor cells (HSPC) and T cells-vldq. This innovative therapy is specifically indicated for use in matched donor hematopoietic stem cell transplantation for adults suffering from hematologic malignancies. This approval marks a significant advancement in…









